EU CHMP recommends approval of Briviact (brivaracetam) for partial-onset epilepsy seizures- UCB
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Briviact (brivaracetam), from UCB, intended for the treatment of partial-onset epilepsy seizures in adult and adolescent patients from 16 years of age.
The benefits with Briviact are its ability to reduce the frequency of partial-onset seizures in epilepsy patients when added to an existing regimen of antiepileptic medicines. The most common side effects are somnolence, dizziness and fatigue. It will be available as 10 mg, 25 mg, 50 mg, 75 mg and 100 mg film-coated tablets, a 10 mg/ml oral solution, and a 10 mg/ml solution for injection/infusion.
Comment: Brivaracetam is seen at UCB as a follow up drug after Keppra (levetiracetam), especially as it claims brivaracetam has a 10-fold higher affinity for synaptic vesicle protein 2A than the older drug, which means that it is more potent in controlling seizure activity.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins